Strs Ohio Buys New Position in Krystal Biotech, Inc. $KRYS

Key Points

• Strs Ohio invested $1.24 million in Krystal Biotech, Inc. by purchasing 6,900 shares during the first quarter, as detailed in a recent SEC filing.
• Institutional investors collectively own 86.29% of Krystal Biotech, with notable positions increased by UBS AM and Nuveen LLC in the first quarter.
• Krystal Biotech reported $1.29 earnings per share for the last quarter, exceeding analysts' expectations of $1.08, alongside revenues of $96.04 million.

Strs Ohio purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,900 shares of the company's stock, valued at approximately $1,244,000.

A number of other hedge funds also recently modified their holdings of the business. Crossmark Global Holdings Inc. raised its position in shares of Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after purchasing an additional 63 shares during the period. Xponance Inc. raised its position in Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock valued at $338,000 after buying an additional 88 shares during the last quarter. Sound View Wealth Advisors Group LLC raised its position in Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after buying an additional 95 shares during the last quarter. New York State Teachers Retirement System raised its position in Krystal Biotech by 0.6% in the 1st quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock valued at $2,881,000 after buying an additional 100 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday. Chardan Capital dropped their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research report on Friday, August 22nd. Bank of America dropped their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Finally, Citigroup reissued a "neutral" rating and set a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average price target of $209.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $2.96 during trading on Friday, reaching $163.57. 811,005 shares of the company's stock were exchanged, compared to its average volume of 333,158. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The company has a market cap of $4.73 billion, a P/E ratio of 33.25 and a beta of 0.66. The firm's 50-day moving average price is $147.67 and its 200 day moving average price is $152.22.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The company had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).